Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety Study of BAT1806 vs Actemra in Healthy Chinese Males
NCT03606876Phase 1Completed
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Jun 2018
- Primary completion
- Jul 2019
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tocilizumab in rheumatoid arthritis (RA) (3 arms), sponsored by Bio-Thera Solutions, Ltd. Primary endpoint: Pharmacokinetics Endpoint. Started Jun 2018; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03606876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03606876.